Posted on 01/07/2010 in Pharmaceutical Company Product News Eisai has published data from a recent clinical trial of Dacogen, its new treatment for elderly patients with acute myeloid leukaemia.
The pharmaceutical company conducted the phase III clinical study in order to establish the treatment's efficacy when compared to either a low-dose chemotherapy agent or a supportive care regimen.
Although the therapy did not demonstrate statistically significant superiority over the alternatives in terms of overall survival, Eisai stated that a "trend was evident".
The drug has already been approved as an injection-based treatment for patients with myelodysplastic syndromes in a number of global territories.
Eisai expressed hope that the data from this trial will support regulatory approvals for the new indication of Dacogen.
It added: "Eisai is committed to identifying potential treatment options for diseases such as acute myeloid leukaemia in keeping with its human healthcare mission of striving to address unmet medical needs for patients and their families."
Last month, the company published new clinical trial data from a phase III study of eribulin mesylate, showing its efficacy as a therapy for breast cancer.Other news stories from 01/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
